

Fig. 1A

Week after Prime Dose Administered




Fig. 1B

Week after Prime Dose Administered




Fig. 1C

Week after Prime Dose Administered




Fig. 1D

Week after Prime Dose Administered




Fig. 1E




Fig. 2A




Fig. 2B
Week after Prime Dose Administered




Fig. 2C

Week after Prime Dose Administered




Fig. 3A




Fig. 3B

Week after Prime Dose Administered

@PJL PRINTINGSCOUT JOBEND

Change in fasting log C-peptide from day 1 till week 24 versus change in CD4+CD25+/CD25+CD25- ratio over the same time period . ($r = 0.55$, p -value < 0.001)




Fig. 4A

Change in fasting log C-peptide from day 1 till week 24 versus change in CD4+CD25+/CD25+CD25- ratio over the same time period for patients who showed a decline in GADA after the second dose of 20ug or 100ug. ($r=0.83$, $p\text{-value}<0.05$).




Fig. 4B Change in CD4+CD25+/CD25+CD25- ratio

HbA1c




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 5D




Fig. 5E




Fig. 5F Months after Prime Dose Administered

Log f-Cpeptide




Fig. 5G




Fig. 5H




Fig. 5I




Fig. 5J




Fig. 5K




Fig. 5K Months after Prime Dose Administered

Log f-Cpeptide/f-glucose

$$\begin{aligned}\text{Units} &= (\text{nmol/l}) * 1000 / \text{mmol/l} \\ &= \text{pmol/l} / \text{mmol/l} \\ &= \text{nmol}\end{aligned}$$




Fig. 5L




Fig. 5N




Fig. 5P




Fig. 5Q Months after Prime Dose Administered

Log GADA




Fig. 5R




Fig. 5T




Fig. 5U Months after Prime Dose Administered




Fig. 5V




Fig. 5W Months after Prime Dose Administered

Lost to follow-up (3/47)

	Number Remaining in Study										Reason
Placebo	13	13	13	12	12	12	12	12	12	12	????
4 microgram	9	9	9	9	8	8	8	8	8	8	?????
20 microgram	8	8	8	8	8	8	8	8	8	8	
100 microgram	9	9	8	8	8	8	8	8	8	8	Adverse event
500 microgram	8	8	8	8	8	8	8	8	8	-	
	0	3	6	9	12	15	18				

Months after Prime Dose Administered

Fig. 5X


Lost to Insulin Treatment (11/44)

	Number Remaining in Study										Lost
Placebo	12	12	11	11	11	11	9	9			3/12 (25%)
4 microgram	8	8	8	6	5	4	4	4			4/8 (50%)
20 microgram	8	8	8	7	7	7	7	7			1/8 (13%)
100 microgram	8	8	7	7	7	7	7	7			1/8 (13%)
500 microgram	8	8	6	6	5	4	-	-			4/8 (50%)
	0	3	6	9	12	15	18				

Months after Prime Dose Administered

Fig. 5Y

Induction of GAD65-specific regulatory T cells modulates diabetes in NOD mice



Tisch et al. (1998) Induction of GAD65-specific regulatory T cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice *Diabetes* 47:894-899

Figure 6 – Induction of GAD65-specific regulatory T cells in NOD Mice




Figure 7 - Patient disposition in Phase II Trial

Log Fasting C-peptide (nmol/l) (Mean \pm SEM)




Figure 8 - C-peptide/glucose at 6 months, 12 months and 18 months

Log fasting C-peptide/fasting glucose (nmol) (Mean \pm SEM)




Figure 9 – Log Fasting C-peptide/fasting glucose at 6 months, 12 months and 18 months




Figure 10 – HbA1c (%) at 6 months, 12 months and 18 months

Log GAD65Ab (Index) (Mean \pm SEM)




Figure 11 – Log GAD65Ab at 6 months, 12 months and 18 months




Figure 12 – Change in CD4+CD25+/CD4+CD25- T cell ratio




Figure 13 – Percent of LADA Patients Receiving Insulin in 24 Months